SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from_____________ to____________

Commission File Number: 0-56615

LONGDUODUO COMPANY LIMITED

(Exact name of registrant as specified in its charter)

Nevada		37-2018431
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

G3-5-8016 Shui’an Town, Ruyi Headquarters Base

Hohhot Economic Development Zone

Inner Mongolia 010000

P.R. China

Office: +86 (0472) 510 4980

(Address, including zip code, and telephone number, including area code,

of Registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
None		None		Not Applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12 b-2 of the Act). Yes ☐ No ☒

(APPLICABLE ONLY TO CORPORATE REGISTRANTS)

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

As of the date of filing of this report, there were outstanding 30,015,036 shares of the issuer’s common stock, par value $0.001 per share.

TABLE OF CONTENTS

		Page
	PART I—FINANCIAL INFORMATION	1
Item 1	Financial Statements.	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	7
Item 4.	Controls and Procedures.	7

	PART II—OTHER INFORMATION	8
Item 1.	Legal Proceedings.	8
Item 1A.	Risk Factors	8
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	8
Item 3.	Defaults Upon Senior Securities.	8
Item 4.	Mine Safety Disclosure	8
Item 5.	Other Information.	8
Item 6.	Exhibits.	8

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

	Page

Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and June 30, 2024	F-1

Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Nine Months Ended March 31, 2025 and 2024 (Unaudited)	F-2

Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the Three and Nine Months Ended March 31, 2025 and 2024 (Unaudited)	F-3

Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2025 and 2024 (Unaudited)	F-4

Notes to Consolidated Financial Statements (Unaudited)	F-5 – F-16

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31, 2025			June 30, 2024
	(Unaudited)
Assets
Current Assets:
Cash and cash equivalents	$	1,456,125		$	1,404,042
Other receivables		68,124			131,376
Prepayments		150,176			124,427
Due from related parties		13,778			-
Total current assets		1,688,203			1,659,845
Property and equipment, net		300,179			353,486
Right-of-use assets		37,035			50,070
Total assets	$	2,025,417		$	2,063,401

Liabilities and Equity
Current Liabilities:
Accounts payable	$	246,570		$	358,613
Deferred revenue		586,460			713,360
Accrued expenses		43,592			50,107
Due to related parties		2,329			2,233
Other payables		638			35,660
Operating lease liabilities, current		18,159			17,618
Other current liabilities		4,015			86,645
Total current liabilities		901,763			1,264,236
Operating lease liabilities, less current portion		18,876			18,314
Total liabilities		920,639			1,282,550

Equity (Deficit):
Preferred stock; $0.001 par value, 30,000,000 shares authorized, no shares issued and outstanding at March 31, 2025 and June 30, 2024		-			-
Common stock; $0.001 par value, 500,000,000 shares authorized; 30,015,036 and 30,005,016 shares issued and outstanding at March 31, 2025 and June 30, 2024, respectively		30,015			30,005
Additional paid-in capital		7,246,719			7,246,729
Accumulated deficit		(6,332,342	)		(6,629,632	)
Accumulated other comprehensive income		53,655			55,413
Total stockholders’ equity attributable to the common stockholders		998,047			702,515
Non-controlling interests		106,731			78,336
Total stockholders’ equity		1,104,778			780,851
Total liabilities and equity	$	2,025,417		$	2,063,401

The accompanying notes are an integral part of these consolidated financial statements.

F-1

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

	For the Three Months Ended March 31,						For the Nine Months Ended March 31,
	2025			2024			2025			2024
Revenues:
Service revenue	$	28,724		$	53,807		$	117,640		$	327,653
Commission revenue		748,996			1,736,277			3,204,647			5,390,407
Total revenue, net		777,720			1,790,084			3,322,287			5,718,060
Cost of revenue:
Cost of service		20,444			38,597			81,501			143,347
Total cost of revenues		20,444			38,597			81,501			143,347
Gross profit		757,276			1,751,487			3,240,786			5,574,713

Selling, general and administrative expenses		876,095			1,032,623			2,819,107			4,026,082
(Loss) income from operations		(118,819	)		718,864			421,679			1,548,631
Other income (expense), net		2,583			(9,603	)		10,756			(144,825	)
(Loss) income before provision for income taxes		(116,236	)		709,261			432,435			1,403,806
Income tax expense		84			191,292			106,660			408,265
Net (loss) income		(116,320	)		517,969			325,775			995,541
Less: net (loss) income attributable to non-controlling interests		(7,216	)		6,425			28,485			51,091
Net (loss) income attributable to common stockholders	$	(109,104	)	$	511,544		$	297,290		$	944,450

Comprehensive income (loss):
Net (loss) income	$	(116,320	)	$	517,969		$	325,775		$	995,541
Foreign currency translation adjustment		13,220			(10,118	)		(1,848	)		(4,761	)
Comprehensive (loss) income		(103,100	)		507,851			323,927			990,780
Less: comprehensive (loss) income attributable to non-controlling interests		(10,874	)		6,344			28,395			50,807
Comprehensive (loss) income attributable to the common stockholders	$	(92,226	)	$	501,507		$	295,532		$	939,973

Basic and diluted income (loss) per share	$	(0.004	)	$	0.017		$	0.010		$	0.031
Weighted average number of shares outstanding-basic and diluted		30,009,469			30,005,016			30,006,500			30,005,016

The accompanying notes are an integral part of these consolidated financial statements.

F-2

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

	Common stock				Additional					Accumulated Other			Total Stockholders’			Non-			Total
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Comprehensive Income			Equity (Deficit)			controlling Interests			Equity (Deficit)
Balance at June 30, 2023		30,005,008	$	30,005	$	7,246,729	$	(7,885,080	)	$	66,389		$	(541,957	)	$	(28,698	)	$	(570,655	)
Net income (loss)		-		-		-		284,217			-			284,217			10,527			294,744
Foreign currency translation adjustment		-		-		-		-			(1,219	)		(1,219	)		71			(1,148	)
Balance at September 30, 2023		30,005,008	$	30,005	$	7,246,729	$	(7,600,863	)	$	65,170		$	(258,959	)	$	(18,100	)	$	(277,059	)
Adjustment for the reverse stock split		8		-		-		-			-			-			-			-
Net income (loss)		-		-		-		148,689			-			148,689			34,139			182,828
Foreign currency translation adjustment		-		-		-		-			6,779			6,779			(274	)		6,505
Balance at December 31, 2023		30,005,016	$	30,005	$	7,246,729	$	(7,452,174	)	$	71,949		$	(103,491	)	$	15,765		$	(87,726	)
Net income (loss)		-		-				511,544			-			511,544			6,425			517,969
Foreign currency translation adjustment		-		-				-			(10,037	)		(10,037	)		(81	)		(10,118	)
Balance at March 31, 2024		30,005,016	$	30,005	$	7,246,729	$	(6,940,630	)	$	61,912		$	398,016		$	22,109		$	420,125

	Common stock				Additional						Accumulated Other			Total			Non-
	Number of Shares		Amount		Paid-in Capital			Accumulated Deficit			Comprehensive Income			Stockholders’ Equity			controlling Interests			Total Equity
Balance at June 30, 2024		30,005,016	$	30,005	$	7,246,729		$	(6,629,632	)	$	55,413		$	702,515		$	78,336		$	780,851
Net income (loss)		-		-		-			(57,303	)		-			(57,303	)		(2,201	)		(59,504	)
Foreign currency translation adjustment		-		-		-			-			44,214			44,214			2,775			46,989
Balance at September 30, 2024		30,005,016	$	30,005	$	7,246,729		$	(6,686,935	)	$	99,627		$	689,426		$	78,910		$	768,336
Net income (loss)		-		-		-			463,697			-			463,697			37,902			501,599
Foreign currency translation adjustment		-		-		-			-			(62,850	)		(62,850	)		793			(62,057	)
Balance at December 31, 2024		30,005,016	$	30,005	$	7,246,729		$	(6,223,238	)	$	36,777		$	1,090,273		$	117,605		$	1,207,878
Shares issued for company acquisition		10,020		10		(10	)		-			-			-			-			-
Net income (loss)		-		-		-			(109,104	)		-			(109,104	)		(7,216	)		(116,320	)
Foreign currency translation adjustment		-		-		-			-			16,878			16,878			(3,658	)		13,220
Balance at March 31, 2025		30,015,036	$	30,015	$	7,246,719		$	(6,332,342	)	$	53,655		$	998,047		$	106,731		$	1,104,778

The accompanying notes are an integral part of these consolidated financial statements

F-3

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Nine Months Ended March 31,
	2025			2024
Cash Flows from Operating Activities
Net income	$	325,775		$	995,541
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		110,203			75,937
Operating lease expense		37,722			35,644
Changes in operating assets and liabilities:
Other receivables		63,860			217
Prepayments		(49,361	)		(192,880	)
Inventories		-			832
Due from related parties		(12,274	)		2,843
Accounts payable		(113,289	)		(417,694	)
Deferred revenue		(128,719	)		546,243
Accrued expenses		(6,626	)		(40,178	)
Due to related parties		(15,521	)		(105,225	)
Security deposits		-			(54,992	)
Other payables		(35,309	)		(34,084	)
Other current liabilities		(83,311	)		176,285
Net cash provided by operating activities		93,150			988,489

Cash Flows from Investing Activities
Purchase of property, plant and equipment		(29,454	)		(248,874	)
Net cash used in investing activities		(29,454	)		(248,874	)

Cash Flows from Financing Activities
Net cash used in Financing Activities		-			-

Effect of exchange rate fluctuation on cash and cash equivalents		(11,613	)		7,084
Net increase in cash and cash equivalents		52,083			746,699

Cash and cash equivalents, beginning of period		1,404,042			1,136,562
Cash and cash equivalents, end of period	$	1,456,125		$	1,883,261

Supplemental disclosure of cash flow information
Cash paid for income taxes	$	186,605		$	408,265
Cash paid for interest expense	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-4

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

NOTE 1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Longduoduo Company Limited (“Longduoduo”, together as a group with Longduoduo’s subsidiaries referred to as the “Company” or “we”) was incorporated in the State of Nevada on October 25, 2021. Acting in a principal capacity, the Company provides customers comprehensive and high-quality preventive healthcare solutions including a wide range of preventive healthcare services, including disease screening healthcare treatment, healthcare products and other services through a network of third-party healthcare service providers. In June 2023, the Company began to engage in agent sales of preventive healthcare solutions on behalf of a third-party provider and earn commissions revenue.

On September 21, 2023, the Company implemented a 1-for-10 reverse split of its outstanding common stock, effective at the close of business on September 26, 2023. The accompanying financial statements have been adjusted to retroactively reflect this reverse stock split.

Longduoduo’s subsidiaries include:

●

Longduoduo Company Limited (Hong Kong) (“Longduoduo HK”), which was established on July 26, 2021 under the laws of Hong Kong. On October 26, 2021, Longduoduo issued 30,000,000 shares of its common stock to the original shareholders of Longduoduo HK, in exchange for 100% of the outstanding shares of Longduoduo HK (the “Share Exchange”).

●

LDD Technology Limited (“LDD”) was established on March 18, 2024 under the laws of British Virgin Islands. On February 19, 2025, Longduoduo issued 10,020 shares of its common stock to the original shareholders of LDD, in exchange for 100% of the outstanding shares of LDD.

●

LDDJK Hong Kong Limited (“LDDJK”) was established on April 9, 2024 under the laws of Hong Kong. LDD has controlled 100% of LDDJK since its inception.

●

Beijing Julong Health Consulting Co., Limited (“Julong”) was established in Beijing, China on July 23, 2024. LDDJK has controlled 100% of Julong since its inception.

●

Beijing Yihua Health Consulting Co., Limited (“Yihua”) was established in Beijing, China on March 14, 2024. On January 7, 2025, Julong acquired all the shares held by the original shareholders of Yihua, and controlled 100% ownership of Yihua.

●

Longduoduo Health Technology Company Limited (“Longduoduo Health Technology”), a privately held Limited Company registered in Inner Mongolia, China on August 20, 2020. On August 16, 2021, Longduoduo HK acquired 100% of the ownership of Longduoduo Health Technology from the original shareholders of Longduoduo Health Technology. On April 2, 2025, Julong acquired 100% of Longduoduo Health Technology from Longduoduo HK.

●

Inner Mongolia Qingguo Health Consulting Company Limited (“Qingguo”), a privately held Limited Company registered in Inner Mongolia, China on June 18, 2020. On September 8, 2020, Longduoduo Health Technology acquired 90% of the ownership of Qingguo from the original shareholders of Qingguo.

●

Inner Mongolia Rongbin Health Consulting Company Limited (“Rongbin”), a privately held Limited Company registered in Inner Mongolia, China on March 18, 2021. Longduoduo Health Technology has controlled 80% of the ownership of Rongbin since established.

●

Inner Mongolia Chengheng Health Consulting Company Limited (“Chengheng”), a privately held Limited Company registered in Inner Mongolia, China on April 9, 2021. Longduoduo Health Technology has controlled 80% of the ownership of Chengheng since established.

●

Inner Mongolia Tianju Health Consulting Company Limited (“Tianju”), a privately held Limited Company registered in Inner Mongolia, China on July 5, 2021. Longduoduo Health Technology has controlled 51% of Tianju since inception.

The transactions summarized above are treated in the Company’s financial statements as a corporate restructuring (reorganization) of entities under common control, as each of the eleven entities have at all times been under the control of Mr. Zhang Liang. Therefore, in accordance with ASC 805-50-45-5, the current capital structure has been retroactively presented in prior periods as if such structure existed at that time, and the entities under common control are presented on a combined basis for all periods. Since all of the subsidiaries were under common control for all periods presented, the results of these subsidiaries are included in the Company’s financial statements for all periods presented.

F-5

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Going concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At June 30, 2023, the Company had cash of $1,136,562, negative working capital of $733,781, and a stockholders’ deficit of $570,655. For the year ended June 30, 2023, the Company had net income of $21,085. The Company’s independent auditor included a going concern emphasis paragraph in its audit report for the years ended June 30, 2023 and June 30, 2022.

Commencing in the last quarter of the fiscal year ended June 30, 2023, the Company changed its business plan to focus on resale of health care services offered by its contractor. The benefits of the change were promptly realized. At June 30, 2024, the Company had cash of $1,404,042, working capital of $395,609, and stockholders’ equity of $780,851. For the year ended June 30, 2024, the Company had net income of $1,363,278. As a result of the improved results, the Company’s independent auditor did not include a going concern emphasis paragraph in its audit report for the year ended June 30, 2024. Although we cannot guarantee that we will continue to achieve profits in our operations, the initial results of the change in our business plan have reduced our doubts concerning the ability of the Company to continue as a going concern.

B. Basis of presentation

The accompanying consolidated financial statements are expressed in U.S. Dollars and have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

C. Principles of consolidation

The consolidated financial statements include the accounts of Longduoduo and its subsidiaries. All significant inter-company accounts and transactions have been eliminated. The consolidated financial statements include 100% of assets, liabilities, and net income or loss of these subsidiaries.

Longduoduo’s subsidiaries as of March 31, 2025 are listed as follows:

Name	Place of Incorporation	Attributable equity interest %		Authorized capital
Longduoduo Company Limited	Hong Kong		100	HK$	10,000
LDD Technology Limited	British Virgin Islands		100	US$	100,000
LDDJK Hong Kong Limited	Hong Kong		100	HK$	10,000
Beijing Julong Health Consulting Co., Limited	China		100		0
Beijing Yihua Health Consulting Co., Limited	China		100		0
Longduoduo Health Technology Company Limited	China		100		0
Inner Mongolia Qingguo Health Consulting Company Limited	China		90		0
Inner Mongolia Rongbin Health Consulting Company Limited	China		80		0
Inner Mongolia Chengheng Health Consulting Company Limited	China		80		0
Inner Mongolia Tianju Health Consulting Company Limited	China		51		0

D. Use of estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however, actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the inventory valuation allowance and the treatment of the shares issued. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.

F-6

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

E. Functional currency and foreign currency translation

An entity’s functional currency is the currency of the primary economic environment in which it operates, normally that is the currency of the environment in which the entity primarily generates and expends cash. Management’s judgment is essential to determine the functional currency by assessing various indicators, such as cash flows, sales price and market, expenses, financing and inter-company transactions and arrangements. The functional currency of the Company is the Chinese Renminbi (“RMB’), except the functional currency of LDDJK is the Hong Kong Dollar and the functional currency of Longduoduo and LDD is the United States Dollar (“US Dollars” or “$”). The reporting currency of these consolidated financial statements is in US Dollars.

The financial statements of Longduoduo’s subsidiaries, which are prepared using the RMB, are translated into the Company’s reporting currency, the US Dollar. Assets and liabilities are translated using the exchange rate at each reporting period end date. Revenue and expenses are translated using weighted average rates prevailing during each reporting period, and stockholders’ equity (deficit) is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income or expense.

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from these transactions are included in operations.

The exchange rates used for foreign currency translation are as follows:

		For the Nine Months Ended March 31,
		2025		2024
		(USD to RMB/USD to HKD)		(USD to RMB/USD to HKD)
Assets and liabilities	period end exchange rate		7.2579/7.7793		7.2221/7.8253
Revenue and expenses	period weighted average		7.2085/7.7846		7.2008/7.8195

F. Concentration of credit risk

The Company maintains cash in state-owned banks in China. In China, the insurance coverage per account of each bank is RMB500,000 (approximately USD$69,000). As of March 31, 2025 and June 30, 2024, the Company had $946,617 and $826,853 cash in excess of the insured amount, respectively.

For each of the nine months ended March 31, 2025 and 2024, one customer accounted for 99.9% of commission revenue.

For the nine months ended March 31, 2025 and 2024, the Company had three major suppliers that each accounted for over 10% of its total cost of revenue.

	For the Nine Months Ended March 31, 2025					For the Nine Months Ended March 31, 2024
	Cost of revenue		Percentage of Cost of revenue			Cost of revenue		Percentage of Cost of revenue
Supplier A	$	5,966		7	%	$	29,454		21	%
Supplier B		32,411		40	%		51,302		36	%
Supplier C		28,641		35	%		43,478		30	%

There are two suppliers that accounted for 53% and 23% of the accounts payable as of March 31, 2025 and one supplier that accounted for 68% of the accounts payable as of June 30, 2024.

G. Cash and cash equivalents

Cash consists of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. All highly liquid investments with original stated maturity of three months or less are classified as cash and cash equivalents. Cash equivalents approximate or equal fair value due to their short-term nature. The Company’s cash and cash equivalents consist of cash on hand and cash in bank as of March 31, 2025 and June 30, 2024.

F-7

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

H. Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis over the useful lives of the assets. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from those accounts and any gain or loss is reflected in income.

The Company capitalizes certain costs associated with the acquisition of software. Once the software is ready for its intended use, these costs are amortized on a straight-line basis over the software’s expected useful life.

The estimated useful lives for property and equipment categories are as follows:

Office equipment and furniture			3 years
Leasehold Improvements			1-5 years

I. Fair value measurements

The Company applies the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Section 820, Fair Value Measurements (“ASC 820”), for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices, other than those in Level 1, in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability,

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

There were no transfers between level 1, level 2 or level 3 measurements for nine months ended March 31, 2025 and 2024.

F-8

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

Financial assets and liabilities of the Company are primarily comprised of cash and cash equivalents, other receivables, due from related parties, accounts payable, accrued expenses, due to related parties, loan from third party, security deposits and other payables. As of March 31, 2025 and June 30, 2024, the carrying values of these financial instruments approximated their fair values due to the short-term maturity of these instruments.

J. Segment information and geographic data

The Company is operating in one segment in accordance with the accounting guidance in FASB ASC Topic 280, Segment Reporting. The Company’s revenues are from customers in the People’s Republic of China (“PRC”). Substantially all assets of the Company are located in the PRC.

K. Revenue recognition

The Company adopted FASB ASC Section 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sales of products and services by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity, and specific criteria have been met for each of the Company’s activities as described below.

Service Revenue

The Company sells healthcare service packages to customers, which represent the rights to services purchased by the Company. The delivery of a healthcare service package to a customer represents a separate performance obligation. The Company’s policy is to recognize service revenue at that time when delivery of the healthcare service package has been contracted for, ownership and risk of loss have been transferred to the customer, and the service has been provided. Accordingly, revenue is recognized at the point in time when the service is provided. Service revenue is recognized when the healthcare service package has been delivered to the customer and there are no remaining performance obligations.

Management regularly reviews the sales returns and allowances based on historical experience. Any subsequent sales returns and cancellations are recognized upon notification from the customers. The liability for sales returns and allowances relating to the sale of healthcare service packages amounted to $609 and $923 as of March 31, 2025 and June 30, 2024, respectively. Management’s provision for sales returns and allowances was 1.41% and 1.13%, respectively, of the total service revenue for the nine months ended March 31, 2025 and 2024.

The Company typically collects fees before delivery of healthcare packages. Amounts received from a customer before the delivery of the healthcare package are recorded as deferred revenue on the Consolidated Balance Sheets.

Commission Revenue

Commencing in the three months ended June 30, 2023, the Company started offering in a sales agent capacity healthcare service and product packages of a third-party provider. The third party is responsible for fulfillment of the services to the customer and the Company has no performance commitment or liability to the customer. The Company receives deposits from the customers, remits to the third-party provider the provider’s contracted amounts, and retains the remaining amounts as commission revenue. The commission revenue is recognized upon acceptance of the customer contract by the third-party provider and is presented on a net basis in the Statement of Operations and Comprehensive Income (Loss).

Cost of Revenues

Cost of service revenue consists primarily of the cost of healthcare service packages purchased from third party healthcare service providers to fulfill contracts with customers.

Cost of product revenue consists primarily of the cost of healthcare products purchased from suppliers. Cost of product revenue is recognized when the product has been delivered to the customer.

F-9

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

L. Income taxes

The Company follows FASB ASC Section 740, Income Taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740-10-30 requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under ASC 740-10-30, tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met.

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or the deferred tax asset valuation allowance.

As a result of the implementation of ASC 740-10, the Company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10. The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation.

M. Earnings (loss) per share

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, Earnings Per Share. ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average common shares outstanding during the period.

Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of contracts to issue common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. The computation of diluted EPS includes the estimated impact of the exercise of contracts to purchase common stock using the treasury stock method and the potential shares of converted common stock associated with the convertible debt using the if-converted method. Potential common shares that have an anti-dilutive effect (i.e., those that increase earnings per share or decrease loss per share) are excluded from the calculation of diluted EPS. As of March 31, 2025 and June 30, 2024, the Company was not party to any contract to issue shares.

N. Recently adopted accounting pronouncements

We do not believe that any recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial position, statements of operations and cash flows.

F-10

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

NOTE 3. PREPAYMENTS

Prepayments represent payments in advance to suppliers for expenses, equipment, leasing and products. As of March 31, 2025 and June 30, 2024 prepayments were $150,176 and $124,427, respectively.

NOTE 4. PROPERTY AND EQUIPMENT

As of March 31, 2025 and June 30, 2024, property and equipment, at cost, consisted of:

	March 31,		June 30,
	2025		2024
Office equipment and furniture	$	488,888	$	461,562
Leasehold improvements		69,524		40,506
Total		558,412		502,068
Accumulated depreciation		258,233		148,582
Total property and equipment, net	$	300,179	$	353,486

The Company recorded depreciation expense of $27,661 for the three months ended March 31, 2025, of which $25,395 was recorded as operating expense and $2,266 was recorded as cost of revenue. The Company recorded depreciation expense of $110,203 for the nine months ended March 31, 2025, of which $103,271 was recorded as operating expense and $6,932 was recorded as cost of revenue.

The Company recorded depreciation expense of $37,234 for the three months ended March 31, 2024, of which $32,835 was recorded as operating expense and $4,399 was recorded as cost of revenue. The Company recorded depreciation expense of $75,937 for the nine months ended March 31, 2024, of which $68,106 was recorded as operating expense and $7,831 was recorded as cost of revenue.

NOTE 5. RELATED PARTY TRANSACTIONS

Due from related parties

Due from related parties consists of the following:

Name of related party	March 31, 2025		June 30, 2024
Zhou Hongxiao	$	13,778	$	-
Total	$	13,778	$	-

Zhou Hongxiao is the CEO of the Company. These advances due from related parties were unsecured, repayable on demand, and bear no interest.

Due to related parties

Due to related parties consists of the following:

Name of related party	March 31, 2025		June 30, 2024
Zhang Liang	$	2,329	$	2,233
Total	$	2,329	$	2,233

Until November 29, 2023, Zhang Liang was the President and Chairman of the Board of Longduoduo. Mr. Zhang Liang controls approximately 51% of Longduoduo’s issued and outstanding common stock. These advances due to related parties are unsecured, repayable on demand, and bear no interest.

F-11

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

NOTE 6. INCOME TAXES

United States

Longduoduo is subject to the U.S. corporation tax rate of 21%.

British Virgin Islands

The Company’ subsidiary, LDD, is incorporated in the BVI and is not subject to tax on income or capital gain. In addition, payments of dividends by LDD to its shareholders are not subject to withholding tax in the BVI.

Hong Kong

Longduoduo HK and LDDJK are incorporated in Hong Kong and are subject to Hong Kong profits tax. They are subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. From year of assessment of 2019/2020 onwards, Hong Kong profits tax rates are 8.25% on assessable profits up to HK$2,000,000, and 16.5% on any part of assessable profits over HK$2,000,000. The Company did not have any income (loss) subject to the Hong Kong profits tax.

China

Longduoduo Health Technology and subsidiaries are subject to a 25% standard enterprise income tax in the PRC. The Company accrued $106,660 and $408,265 of PRC income tax for the nine months ended March 31, 2025 and 2024.

A summary of income (loss) before income taxes for domestic and foreign locations for the three and nine months ended March 31, 2025 and 2024 is as follows:

	For the Three Months Ended March 31,
	2025			2024
United States	$	(54,908	)	$	(48,021	)
Foreign		(61,328	)		757,282
Income (loss) before income taxes	$	(116,236	)	$	709,261

	For the Nine Months Ended March 31,
	2025			2024
United States	$	(193,408	)	$	(183,687	)
Foreign		625,843			1,587,493
Income (loss) before income taxes	$	432,435		$	1,403,806

F-12

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

The difference between the U.S. federal statutory income tax rate and the Company’s effective tax rate was as follows:

	For the Nine Months Ended March 31,
	2025			2024
Income tax (benefit) at USA statutory rate		(21	)%		(21	)%
U.S. valuation allowance		21	%		21	%
Income tax (benefit) at USA effective rate		(0	)%		(0	)%

The difference between the PRC statutory income tax rate and the PRC effective tax rate was as follows:

	For the Nine Months Ended March 31,
	2025			2024
Income tax (benefit) at PRC statutory rate		25	%		25	%
Utilization of net operating loss carry forward		-	%		(1	)%
PRC valuation allowance		(8	)%		2	%
Income tax (benefit) at PRC effective rate		17	%		26	%

The Company did not recognize deferred tax assets since it is not more likely than not that it will realize such deferred taxes. The deferred tax would apply to Longduoduo in the U.S. and Longduoduo Health Technology and subsidiaries in China.

As of March 31, 2025, Longduoduo Health Technology and its subsidiaries have total net operating loss carry forwards of approximately $395,203 in the PRC that expire through 2030. Due to the uncertainty of utilizing these carry forwards, the Company provided a 100% allowance on all deferred tax assets of approximately $11,856 and $9,696 related to its operations in the PRC as of March 31, 2025 and June 30, 2024, respectively. The PRC valuation allowance has increased by $0 and decreased by $38,681 for the nine months ended March 31, 2025 and 2024, respectively.

The Company incurred losses from its United States operations during the nine months ended March 31, 2025 of approximately $193,408. The Company’s United States operations consist solely of ownership of its foreign subsidiaries, and the losses arise from administration expenses. Accordingly, management provided a 100% valuation allowance of approximately $254,051 and $213,436 against the deferred tax assets related to the Company’s United States operations as of March 31, 2025 and June 30, 2024, respectively, because the deferred tax benefits of the net operating loss carry forwards in the United States are not likely to be utilized. The US valuation allowance has increased by approximately $40,616 and $38,574 for the nine months ended March 31, 2025, and 2024, respectively.

F-13

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

The Company is subject to examination by the Internal Revenue Service (IRS) in the United States as well as by the taxing authorities in China, where the Company has significant business operations. The table below presents the earliest tax year that remains subject to examination by major jurisdiction.

		Earliest tax year that remains subject to examination
U.S. Federal		June 30, 2021
China		June 30, 2020

NOTE 7. LEASES

On November 20, 2024, Chengheng leased an office space (approximately 611 square meters) under an operating lease agreement from Dongsheng District Baiyan Health Consultation Department. Under the terms of the agreement, Chengheng is committed to make lease payments of approximately $16,720 (RMB120,000) for the period between November 20, 2024 and November 20, 2025.

On March 11 of 2025, Longduoduo Health Technology leased office space (approximately 150 square meters) under an operating lease agreement with Liu Libao. Under the terms of the agreement, Longduoduo Health Technology is committed to make lease payments of approximately $4,160 (RMB30,000) for the period between March 11, 2025 and March 10, 2026.

On April 1 of 2024, Tianju leased office space (approximately 595 square meters) under an operating lease agreement with Han Ruijun. Under the terms of the agreement, Tianju is committed to make lease payments of approximately $19,000 (RMB137,000) annually for the period between April 1, 2024 and March 31, 2027.

On August 14, 2024, Qingguo leased office space (approximately 482 square meters) under an operating lease agreement with Inner Mongolia Chuangfuhui Enterprise Management Co., Ltd. Under the terms of the agreement, Qingguo is committed to make lease payments of approximately $30,510 (RMB 220,000) for the period between September 10, 2024 and September 10, 2025.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company did not combine lease and non-lease components.

Most leases do not include options to renew. The exercise of lease renewal options has to be agreed to by the lessors. The depreciable life of assets and leasehold improvements are limited by the term of leases, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease expense is recognized on a straight-line basis over the term of the lease. Lease expense related to noncancelable operating leases was $43,271 and $35,644 for the nine months ended March 31, 2025 and 2024, respectively.

Balance sheet information related to the Company’s leases is presented below:

	March 31, 2025		June 30, 2024
Assets
Operating lease right of use assets	$	37,035	$	50,070
Liabilities
Operating lease liabilities – current	$	18,159	$	17,618
Operating lease liabilities – non-current		18,876		18,314
Total Operating lease liabilities	$	37,035	$	35,932

F-14

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

As most of the Company’s leases do not provide an implicit rate, the Company uses 1-5 years borrowing rate from bank of 3.95% and 4.75% based on the information available at commencement date in determining the present value of lease payments.

Maturities of lease liabilities are as follows:

For the years ending March 31:
2026	$	18,876
2027		18,876
Total lease payments		37,752
Less: imputed interest		(717	)
Total lease liabilities	$	37,035

NOTE 8. CONTINGENCIES

Contingencies

Certain conditions may exist as of the date the consolidated financial statements are issued which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.

Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

The Company was not subject to any material loss contingency as of March 31, 2025 and June 30, 2024.

NOTE 9. STOCKHOLDERS’ EQUITY

On September 21, 2023, the Company filed with the Nevada Secretary of State a Certificate of Change Pursuant to NRS 78.209. The Certificate of Change provided for a 1-for-10 reverse split of the Registrant’s outstanding common stock effective at the close of business on September 26, 2023. The Certificate of Change did not change the number of authorized shares of Common Stock, which remained 500,000,000 shares. No fractional shares were issued in connection with the reverse stock split; any fractional shares that resulted from the reverse split were rounded up to the nearest whole share. The accompanying financial statements have been adjusted to retroactively reflect this reverse stock split.

On February 19, 2025, Longduoduo issued 10,020 shares of its common stock to the original shareholders of LDD, in exchange for 100% of the outstanding shares of LDD.

F-15

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(UNAUDITED)

NOTE 10. BASIC AND DILUTED EARNINGS PER SHARE

Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise shares issuable upon the exercise of share-based awards, using the treasury stock method. The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations is shown as follows:

	For the Three Months Ended March 31,
	2025			2024
Numerator:
Net income(loss) attributable to common stockholders	$	(109,104	)	$	511,544
Denominator:
Basic and diluted weighted-average number of shares outstanding		30,009,469			30,005,016
Net income per share:
Basic and diluted	$	(0.004	)	$	0.017

	For the Nine Months Ended March 31,
	2025		2024
Numerator:
Net income attributable to common stockholders	$	297,290	$	944,450
Denominator:
Basic and diluted weighted-average number of shares outstanding		30,006,500		30,005,016
Net income per share:
Basic and diluted	$	0.010	$	0.031

NOTE 11. NON-CONTROLLING INTERESTS

Qingguo, Chengheng, Rongbin and Tianju are the Company’s majority-owned subsidiaries which are consolidated in the Company’s financial statements with non-controlling interests recognized. The Company holds 90%, 80%, 80% and 51% interest of Qingguo, Chengheng, Rongbin and Tianju as of March 31, 2025, respectively.

As of March 31, 2025 and June 30, 2024, the non-controlling interests in the consolidated balance sheet was $106,731 and 78,336, respectively.

For the three months ended March 31, 2025, the comprehensive loss attributable to common stockholders and non-controlling interests were $92,226 and $10,874, respectively. For the nine months ended March 31, 2025, the comprehensive income attributable to common stockholders and non-controlling interests were $295,532 and $28,395, respectively.

For the three months ended March 31, 2024, the comprehensive income attributable to common stockholders and non-controlling interests were $501,507 and $6,344, respectively. For the nine months ended March 31, 2024, the comprehensive income attributable to common stockholders and non-controlling interests were $939,973 and $50,807, respectively.

NOTE 12. SUBSEQUENT EVENTS

On April 2, 2025, Julong acquired 100% of Longduoduo Health Technology from Longduoduo HK.

Management has evaluated subsequent events through the date which the consolidated financial statements were available to be issued. There are no other subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

F-16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of such financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. On an ongoing basis, we evaluate these estimates, including those related to useful lives of real estate assets, bad debts, impairment, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates.

Application of Critical Accounting Policies

The discussion and analysis of the Company’s financial condition and results of operations is based upon its condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.

In connection with the preparation of our financial statements for the three months ended March 31, 2025, there was no accounting estimate made which was (a) subject to a high degree of uncertainty and (b) material to our results.

Results of Operations

Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024

The following table shows key components of the unaudited results of operations during the three months ended March 31, 2025 and 2024:

	For the Three Months Ended
	March 31,
	2025			2024			Change
	(Unaudited)			(Unaudited)			$			%
Total revenue	$	777,720		$	1,790,084		$	(1,012,364	)		(57	)%
Cost of revenue		20,444			38,597			(18,153	)		(47	)%
Gross Profit		757,276			1,751,487			(994,211	)		(57	)%
Total operating expenses		876,095			1,032,623			(156,528	)		(15	)%
Loss from operations		(118,819	)		718,864			(837,683	)		(117	)%
Other income (expense), net		2,583			(9,603	)		12,186			(127	)%
Income (loss) before income taxes		(116,236	)		709,261			(825,497	)		(116	)%
Income tax		84			191,292			(191,208	)		(100	)%
Net income (loss)	$	(116,320	)	$	517,969		$	(634,289	)		(122	)%

During the three months ended March 31, 2025, our total revenue was $777,720, of which $28,724 was attributable to the sale of healthcare services, primarily derived from sales of “Immunological Ozonated Autohemotherapy”, “Meridian-regulating and Consciousness-restoring Iatrotechnics”, “Assay”, “PRP” and other healthcare services. The remaining $748,996 of revenue was attributable to commissions earned by the Company from its service as sales agent for Inner Mongolia Honghai Health Management Co., Ltd. (“Honghai”). In June of 2023, the Company began to engage in the sales agent business and focused on the sales of preventive healthcare solutions administered by Honghai, with whom we have a Sales Agency Agreement. As of March 31, 2025, we operate through seven entities: Longduoduo Health Technology, Tianju, Qingguo, Rongbin, Chengheng, Julong and Yihua which are established in Ordos, Ulanqab, Huhhot, Baotou, Ordos and Beijing, respectively, which include four of the largest cities in Inner Mongolia, and the capital of China.

Quarter to quarter revenue fell by 57% as compared with the operating revenue of $1,790,084 for the three months ended March 31, 2024. The decrease was primarily attributable to the fact that Neimenggu Province was emerging from the pandemic during the three months ended March 31, 2024. A large number of customers received services during that quarter that they had earlier paid for but could not receive. This resulted in a surge in revenue during the three months ended March 31, 2024. One other important factor influencing revenue in the recent quarter is the impact of the economic environment, which has led to a decrease in customer health expenditures. Management believes that the government has recently introduced policies to promote economic recovery, but it may take some time for the situation to truly improve. Meanwhile, as we wait for the economy to revive, the Company is implementing plans to improve its operations by adjusting its operational policies.

Cost of revenue relates solely to our service revenue, and mainly consists of our payments to the third-party healthcare service providers who perform healthcare services for our customers. During the three months ended March 31, 2025, our cost of revenue was $20,444, with the result that our gross profit from service revenue was $8,280 (a gross margin of 29%). By comparison, our gross profit from service revenue for the three months ended March 31, 2024 was $38,597, representing 28% of service revenue for that quarter.

When our net service revenue in the three months ended March 31, 2025 was combined with commission revenue (for which there is no cost of revenue), we achieved gross profit of $757,276. However, we realized only a $118,819 loss from operations for the three months ended March 31, 2025 because the Company incurred significant marketing expense in connection with establishing its brand as a new company. The Company will continue to invest heavily in advertising and promotion expenses in the near future as it continues to establish and expand its brand and products and services.

Our operating expenses consist primarily of advertising and promotion expenses, salaries and benefits, office expenses, professional fees and depreciation. Our operating expenses during the three months ended March 31, 2025 decreased by $156,528, primarily attributable to:

●

$478,981 in advertising and promotion expenses incurred during the three months ended March 31, 2025, compared to $634,316 recorded during the three months ended March 31, 2024. The decrease was primarily attributable to a tactical decision by Management to reduce marketing expense while we await an economic recovery that will fund an increase in non-essential medical expenditures. Over the longer term, we intend to continue to devote available resources to expanded advertising and promotion expense for the purpose of achieving a broader market.

Our net loss for the three months ended March 31, 2025 was $116,320, compared to a net income of $517,969 for the three months ended March 31, 2024. As noted above, the current economic environment has led to reduction in patient use of medical services. The government has recently introduced many policies to promote economic recovery. But it may take some time for the situation to truly improve. Also, the Company intends to improve its operations by adjusting its operational policies.

Our reporting currency is the U.S. dollar. Our local currency, the Renminbi (RMB), is our functional currency. Results of operations and cash flow are translated at average exchange rates during the period being reported upon, and assets and liabilities are translated at the unified exchange rate as quoted by OANDA on the balance sheet date. Translation adjustments resulting from this process are included in other comprehensive income (loss). For the three months ended March 31, 2025 and 2024, foreign currency translation adjustments of $13,220 and $(10,118), respectively, have been reported as other comprehensive income (loss) in the consolidated statement of operations and comprehensive income (loss).

Nine Months Ended March 31, 2025 Compared to Nine Months Ended March 31, 2024

The following table shows key components of the unaudited results of operations during the nine months ended March 31, 2025 and 2024:

	For the Nine Months Ended
	March 31,
	2025		2024			Change
	(Unaudited)		(Unaudited)			$			%
Total revenue	$	3,322,287	$	5,718,060		$	(2,395,773	)		(42	)%
Cost of revenue		81,501		143,347			(61,846	)		(43	)%
Gross Profit		3,240,786		5,574,713			(2,333,927	)		(42	)%
Total operating expenses		2,819,107		4,026,082			(1,206,975	)		(30	)%
Loss from operations		421,679		1,584,631			(1,126,952	)		(73	)%
Other income (expense), net		10,756		(144,825	)		155,581			(107	)%
Loss before income taxes		432,435		1,403,806			(971,371	)		(69	)%
Income tax		106,660		408,265			(301,605	)		(74	)%
Net income	$	325,775	$	995,541		$	(669,766	)		(67	)%

During the nine months ended March 31, 2025, our total revenue was $3,322,287, of which $117,640 was attributable to the sale of healthcare services, primarily derived from sales of “Immunological Ozonated Autohemotherapy”, “Meridian-regulating and Consciousness-restoring Iatrotechnics”, “Assay”, “PRP” and other healthcare services. The remaining $3,204,647 of revenue was attributable to commissions earned by the Company from its service as sales agent for Honghai. In June of 2023, the Company began to engage in the sales agent business and focused on the sales of preventive healthcare solutions administered by Honghai, with whom we have a Sales Agency Agreement. As of March 31, 2025, we operate through seven entities: Longduoduo Health Technology, Tianju, Qingguo, Rongbin，Chengheng, Julong and Yihua which are established in Ordos, Ulanqab, Huhhot, Baotou,Ordos and Beijing, respectively, which include four of the largest cities in Inner Mongolia, and the capital of China.

Period to period revenue fell by 42% as compared with the operating revenue of $5,718,060 for the nine months ended March 31, 2024. The decrease was primarily attributable to the fact that Neimenggu Province was emerging from the pandemic during the nine months ended March 31, 2024. A large number of customers received services during that period that they had earlier paid for but could not receive. This resulted in a surge in revenue during the nine months ended March 31, 2024. One other important factor influencing revenue in the recent period is the impact of the economic environment, which has led to a decrease in customer health expenditures. Management believes that the government has recently introduced policies to promote economic recovery, but it may take some time for the situation to truly improve. Meanwhile, as we wait for the economy to revive, the Company is implementing plans to improve its operations by adjusting its operational policies.

Cost of revenue relates solely to our service revenue, and mainly consists of our payments to the third-party healthcare service providers who perform healthcare services for our customers. During the nine months ended March 31, 2025, our cost of revenue was $81,501, with the result that our gross profit from service revenue was $36,139 (a gross margin of 31%). By comparison, our gross profit from service revenue for the nine months ended March 31, 2024 was $184,306, representing 56% of service revenue for that quarter.

When our net service revenue in the nine months ended March 31, 2025 was combined with commission revenue (for which there is no cost of revenue), we achieved gross profit of $3,240,786. However, we realized only a $421,679 income from operations for the nine months ended March 31, 2025 because the Company incurred significant marketing expense in connection with establishing its brand as a new company. The Company will continue to invest heavily in advertising and promotion expenses in the near future as it continues to establish and expand its brand and products and services.

Our operating expenses consist primarily of advertising and promotion expenses, salaries and benefits, office expenses, professional fees and depreciation and amortization. Our operating expenses during the nine months ended March 31, 2025 decreased by $1,206,975, primarily attributable to:

●

$1,557,417 in advertising and promotion expenses incurred during the nine months ended March 31, 2025, compared to $2,667,233 recorded during the nine months ended March 31, 2024. The decrease was primarily attributable to a tactical decision by Management to reduce marketing expense while we await an economic recovery that will fund an increase in non-essential medical expenditures. Over the longer term, we intend to continue to devote available resources to expanded advertising and promotion expense for the purpose of achieving a broader market.

●

$429,089 in salaries and benefit expenses in the nine months ended March 31, 2025, compared to $494,416 during the nine months ended March 31, 2024. The decrease in our labor costs was primarily caused by the company decreasing the number of employees due to adjustments in its operational policies.

●

$537,573 in office expenses during the nine months ended March 31, 2025, compared to $599,169 during the nine months ended March 31, 2024. The decrease was mainly attributable to the fact that the decline of business has led to a decrease in daily expenses.

Our net income for the nine months ended March 31, 2025 was $325,775, compared to a net income of $995,541 for the nine months ended March 31, 2024. As noted above, the current economic environment has led to reduction in patient use of medical services. The government has recently introduced many policies to promote economic recovery. But it may take some time for the situation to truly improve. Also, the Company intends to improve its operations by adjusting its operational policies.

Our reporting currency is the U.S. dollar. Our local currency, the Renminbi (RMB), is our functional currency. Results of operations and cash flow are translated at average exchange rates during the period being reported upon, and assets and liabilities are translated at the unified exchange rate as quoted by OANDA on the balance sheet date. Translation adjustments resulting from this process are included in other comprehensive income (loss). For the nine months ended March 31, 2025 and 2024, foreign currency translation adjustments of $(1,848) and $(4,761), respectively, have been reported as other comprehensive income (loss) in the consolidated statement of operations and comprehensive income (loss).

Liquidity and Capital Resources

As of March 31, 2025, the Company had $1,456,125 in cash and cash equivalents, an increase of $52,083 since the previous fiscal year-end. On the same date, we had a working capital of $786,440, an increase of $395,609 since June 30, 2024. The increase in working capital occurred primarily because customers used $128,719 in prepayments to purchase services and the Company reduced its accounts payable balance by $113,289. Nevertheless, our March 31, 2025 balance sheet included only $150,176 of prepayments among our current assets, while recording $586,460 of deferred revenue among our current liabilities. Going forward, we will strive to achieve a better balance of customer deposits and prepayments; but we will achieve that better balance only when profits from operations and funds from financing are adequate to support the expansion effort that will be necessary for successful operations.

We anticipate that our future liquidity requirements will arise from the need to fund our growth, pay current obligations and future capital expenditures. The primary sources of funding for such requirements are expected to be cash generated from operations and additional funds from a public offering and/or debt financing. We expect Zhang Liang, our majority shareholder, to continue to provide support in the future, if needed. However, we can provide no assurances that we will be able to generate sufficient cash flows from operations and/or obtain additional financing on terms satisfactory to us, if at all, to remain a going concern.

Cash Flows

The following unaudited table summarizes our cash flows for the nine months ended March 31, 2025 and 2024.

	For the Nine Months Ended March 31,
	2025			2024
	(Unaudited)			(Unaudited)			Change
Net cash provided by operating activities	$	93,150		$	988,489		$	(895,339	)
Net cash used in investing activities		(29,454	)		(248,874	)		219,420
Effect of exchange rate fluctuation on cash and cash equivalents		(11,613	)		7,084			(18,697	)
Net decrease in cash and cash equivalents		52,083			746,699			(694,616	)
Cash and cash equivalents, beginning of period		1,404,042			1,136,562			267,480
Cash and cash equivalents, end of period	$	1,456,125		$	1,883,261		$	(427,136	)

Net Cash Provided by Operating Activities

For the nine months ended March 31, 2025 our operating activities provided $93,150 in cash, compared to $988,489 provided by operating activities for the nine months ended March 31, 2024. The cash inflow that we realized during the nine months ended March 31, 2025 was less than the net income of $325,775 recorded for that period primarily due to a $128,719 reduction in the amount of deposits by customers for future services and the Company’s use of cash to reduce its accounts payable balance by $113,289.

By comparison, during the nine months ended March 31, 2024 we received prepayments from customers totaling $546,243 and used $192,880 of that cash to prepay the cost of services we would sell. This caused us to finish that period with a healthy cash balance but negative working capital.

Net Cash Used in Investing Activities

Net cash used in investing activities for the nine months ended March 31, 2025 was $29,454, compared to $248,874 for the nine months ended March 31, 2024. In both periods, the cash was used for the purchase of fixed assets and office decoration.

Trends, Events and Uncertainties

The U.S. government, including the SEC, has made statements and taken actions that have led to changes in relations between the U.S. and China, and will impact companies with connections to the United States or China. Those actions by the U.S. government included imposing several rounds of tariffs affecting certain products manufactured in China and imposing sanctions and restrictions in relation to China. Actions by the SEC included issuing statements indicating that it would make enhanced review of companies with significant China-based operations. It is unknown whether and to what extent new legislation, executive orders, tariffs, laws or regulations will be adopted, or the effect that any such actions would have on U.S.-domiciled companies with significant connections to China, our industry or on us. Any unfavorable government policies on cross-border relations, including increased scrutiny of companies with significant China-based operations, capital controls or tariffs, may affect our ability to raise capital and the market price of our shares. If any new legislation, executive orders, tariffs, laws and/or regulations are implemented, if existing trade agreements are renegotiated, or if the U.S. or Chinese governments take retaliatory actions due to the recent U.S.-China tensions, such changes could have an adverse effect on our business, financial condition and results of operations, our ability to raise capital and the market price of our shares. Changes in United States and China relations and/or regulations may adversely impact our business, our operating results, our ability to raise capital and the market price of our shares.

Other than the factors listed above we do not know of any trends, events or uncertainties that have had or are reasonably expected to have a material impact on our net sales or revenues or income from continuing operations.

Recent Accounting Pronouncements

There were no recent accounting pronouncements that we expect to have a material effect on the Company’s financial position or results of operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management maintains disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that the material information required to be disclosed by us in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

Under the supervision and with the participation of our management team, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of March 31, 2025. Based on this evaluation, we concluded that our disclosure controls and procedures have the following material weaknesses:

●

The relatively small number of employees who are responsible for accounting functions prevents us from segregating duties within our internal control system.

●

Our internal financial staff lack expertise in identifying and addressing complex accounting issues under U.S. Generally Accepted Accounting Principles.

●

Our Chief Financial Officer is not familiar with the accounting and reporting requirements of a U.S. public company.

●

We have not developed sufficient documentation concerning our existing financial processes, risk assessment and internal controls.

Based on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company’s system of disclosure controls and procedures was not effective as of March 31, 2025 for the purposes described in this paragraph.

Changes in Internal Control over Financial Reporting

During the period covered by this report, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows.

Item 1A. Risk Factors.

There have been no material changes from the risk factors included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024, as filed with the SEC on October 15, 2024.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds.

During the quarter ended March 31, 2025, the Company did not complete any unregistered sales of equity securities that was not reported in a Current Report on Form 8-K.

The Company did not repurchase any of its equity securities that were registered under Section 12 of the Securities Act during the quarter ended March 31, 2025.

Item 3. Defaults upon Senior Securities.

Not applicable

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information.

During the quarter ended March 31, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

INDEX TO EXHIBITS

Exhibit No.		Description of Exhibit
31.1		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LONGDUODUO COMPANY LIMITED

Signature	Title	Date

/s/ Zhou Hongxiao	Chief Executive Officer	May 14, 2025
Zhou Hongxiao	(Principal Executive Officer)

/s/ Kang Liping	Chief Financial Officer	May 14, 2025
Kang Liping	(Principal Financial and Accounting Officer)

0001892316 false Q3 --06-30 0001892316 2024-07-01 2025-03-31 0001892316 2025-05-14 0001892316 2025-03-31 0001892316 2024-06-30 0001892316 us-gaap:RelatedPartyMember 2025-03-31 0001892316 us-gaap:RelatedPartyMember 2024-06-30 0001892316 lddc:ServiceRevenueMember 2025-01-01 2025-03-31 0001892316 lddc:ServiceRevenueMember 2024-01-01 2024-03-31 0001892316 lddc:ServiceRevenueMember 2024-07-01 2025-03-31 0001892316 lddc:ServiceRevenueMember 2023-07-01 2024-03-31 0001892316 lddc:CommissionRevenueMember 2025-01-01 2025-03-31 0001892316 lddc:CommissionRevenueMember 2024-01-01 2024-03-31 0001892316 lddc:CommissionRevenueMember 2024-07-01 2025-03-31 0001892316 lddc:CommissionRevenueMember 2023-07-01 2024-03-31 0001892316 2025-01-01 2025-03-31 0001892316 2024-01-01 2024-03-31 0001892316 2023-07-01 2024-03-31 0001892316 lddc:CostOfServiceMember 2025-01-01 2025-03-31 0001892316 lddc:CostOfServiceMember 2024-01-01 2024-03-31 0001892316 lddc:CostOfServiceMember 2024-07-01 2025-03-31 0001892316 lddc:CostOfServiceMember 2023-07-01 2024-03-31 0001892316 us-gaap:CommonStockMember 2023-06-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001892316 us-gaap:RetainedEarningsMember 2023-06-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001892316 us-gaap:ParentMember 2023-06-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-06-30 0001892316 2023-06-30 0001892316 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001892316 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001892316 us-gaap:ParentMember 2023-07-01 2023-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001892316 2023-07-01 2023-09-30 0001892316 us-gaap:CommonStockMember 2023-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001892316 us-gaap:RetainedEarningsMember 2023-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001892316 us-gaap:ParentMember 2023-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-09-30 0001892316 2023-09-30 0001892316 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001892316 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 2023-12-31 0001892316 us-gaap:ParentMember 2023-10-01 2023-12-31 0001892316 us-gaap:NoncontrollingInterestMember 2023-10-01 2023-12-31 0001892316 2023-10-01 2023-12-31 0001892316 us-gaap:CommonStockMember 2023-12-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001892316 us-gaap:RetainedEarningsMember 2023-12-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001892316 us-gaap:ParentMember 2023-12-31 0001892316 us-gaap:NoncontrollingInterestMember 2023-12-31 0001892316 2023-12-31 0001892316 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001892316 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001892316 us-gaap:ParentMember 2024-01-01 2024-03-31 0001892316 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001892316 us-gaap:CommonStockMember 2024-03-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001892316 us-gaap:RetainedEarningsMember 2024-03-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001892316 us-gaap:ParentMember 2024-03-31 0001892316 us-gaap:NoncontrollingInterestMember 2024-03-31 0001892316 2024-03-31 0001892316 us-gaap:CommonStockMember 2024-06-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001892316 us-gaap:RetainedEarningsMember 2024-06-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001892316 us-gaap:ParentMember 2024-06-30 0001892316 us-gaap:NoncontrollingInterestMember 2024-06-30 0001892316 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001892316 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001892316 us-gaap:ParentMember 2024-07-01 2024-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001892316 2024-07-01 2024-09-30 0001892316 us-gaap:CommonStockMember 2024-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001892316 us-gaap:RetainedEarningsMember 2024-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001892316 us-gaap:ParentMember 2024-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2024-09-30 0001892316 2024-09-30 0001892316 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001892316 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-01 2024-12-31 0001892316 us-gaap:ParentMember 2024-10-01 2024-12-31 0001892316 us-gaap:NoncontrollingInterestMember 2024-10-01 2024-12-31 0001892316 2024-10-01 2024-12-31 0001892316 us-gaap:CommonStockMember 2024-12-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001892316 us-gaap:RetainedEarningsMember 2024-12-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001892316 us-gaap:ParentMember 2024-12-31 0001892316 us-gaap:NoncontrollingInterestMember 2024-12-31 0001892316 2024-12-31 0001892316 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001892316 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001892316 us-gaap:ParentMember 2025-01-01 2025-03-31 0001892316 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001892316 us-gaap:CommonStockMember 2025-03-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001892316 us-gaap:RetainedEarningsMember 2025-03-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001892316 us-gaap:ParentMember 2025-03-31 0001892316 us-gaap:NoncontrollingInterestMember 2025-03-31 0001892316 2023-09-21 2023-09-21 0001892316 lddc:LongduoduoCompanyLimitedMember 2021-10-26 2021-10-26 0001892316 lddc:LongduoduoCompanyLimitedMember 2021-10-26 0001892316 lddc:LDDTechnologyLimitedMember 2025-02-19 2025-02-19 0001892316 lddc:LDDTechnologyLimitedMember 2025-02-19 0001892316 lddc:LDDJKHongKongLimitedMember 2024-04-09 0001892316 lddc:BeijingJulongHealthConsultingCoLimitedJulongMember 2024-07-23 0001892316 lddc:BeijingYihuaHealthConsultingCoLimitedYihuaMember 2025-01-07 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember 2021-08-16 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember us-gaap:SubsequentEventMember 2025-04-02 0001892316 lddc:InnerMongoliaQingguoHealthConsultingCompanyLimitedMember 2020-09-08 0001892316 lddc:InnerMongoliaRongbinHealthConsultingCompanyLimitedMember 2021-03-18 0001892316 lddc:InnerMongoliaChenghengHealthConsultingCompanyLimitedMember 2021-04-09 0001892316 lddc:InnerMongoliaTianjuHealthConsultingCompanyLimitedMember 2021-07-05 0001892316 2022-07-01 2023-06-30 0001892316 2023-07-01 2024-06-30 0001892316 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember lddc:OneSupplierMember 2024-07-01 2025-03-31 0001892316 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember lddc:TwoSupplierMember 2024-07-01 2025-03-31 0001892316 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember lddc:OneSupplierMember 2023-07-01 2024-06-30 0001892316 lddc:LongduoduoCompanyLimitedMember 2024-07-01 2025-03-31 0001892316 lddc:LongduoduoCompanyLimitedMember 2025-03-31 0001892316 lddc:LDDTechnologyLimitedMember 2024-07-01 2025-03-31 0001892316 lddc:LDDTechnologyLimitedMember 2025-03-31 0001892316 lddc:LDDJKHongKongLimitedMember 2024-07-01 2025-03-31 0001892316 lddc:LDDJKHongKongLimitedMember 2025-03-31 0001892316 lddc:BeijingJulongHealthConsultingCoLimitedJulongMember 2024-07-01 2025-03-31 0001892316 lddc:BeijingJulongHealthConsultingCoLimitedJulongMember 2025-03-31 0001892316 lddc:BeijingYihuaHealthConsultingCoLimitedYihuaMember 2024-07-01 2025-03-31 0001892316 lddc:BeijingYihuaHealthConsultingCoLimitedYihuaMember 2025-03-31 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember 2024-07-01 2025-03-31 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember 2025-03-31 0001892316 lddc:InnerMongoliaQingguoHealthConsultingCompanyLimitedMember 2024-07-01 2025-03-31 0001892316 lddc:InnerMongoliaQingguoHealthConsultingCompanyLimitedMember 2025-03-31 0001892316 lddc:InnerMongoliaRongbinHealthConsultingCompanyLimitedMember 2024-07-01 2025-03-31 0001892316 lddc:InnerMongoliaRongbinHealthConsultingCompanyLimitedMember 2025-03-31 0001892316 lddc:InnerMongoliaChenghengHealthConsultingCompanyLimitedMember 2024-07-01 2025-03-31 0001892316 lddc:InnerMongoliaChenghengHealthConsultingCompanyLimitedMember 2025-03-31 0001892316 lddc:InnerMongoliaTianjuHealthConsultingCompanyLimitedMember 2024-07-01 2025-03-31 0001892316 lddc:InnerMongoliaTianjuHealthConsultingCompanyLimitedMember 2025-03-31 0001892316 currency:CNY lddc:AssetsAndLiabilitiesMember 2025-03-31 0001892316 currency:USD lddc:AssetsAndLiabilitiesMember 2025-03-31 0001892316 currency:CNY lddc:AssetsAndLiabilitiesMember 2024-03-31 0001892316 currency:USD lddc:AssetsAndLiabilitiesMember 2024-03-31 0001892316 currency:CNY lddc:RevenueAndExpensesMember 2025-03-31 0001892316 currency:USD lddc:RevenueAndExpensesMember 2025-03-31 0001892316 currency:CNY lddc:RevenueAndExpensesMember 2024-03-31 0001892316 currency:USD lddc:RevenueAndExpensesMember 2024-03-31 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierAMember 2024-07-01 2025-03-31 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierAMember 2023-07-01 2024-03-31 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierBMember 2024-07-01 2025-03-31 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierBMember 2023-07-01 2024-03-31 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierCMember 2024-07-01 2025-03-31 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierCMember 2023-07-01 2024-03-31 0001892316 us-gaap:OfficeEquipmentMember 2025-03-31 0001892316 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2025-03-31 0001892316 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2025-03-31 0001892316 us-gaap:OfficeEquipmentMember 2024-06-30 0001892316 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001892316 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001892316 lddc:MrZhangLiangMember 2023-11-29 2023-11-29 0001892316 lddc:ZhouHongxiaoMember 2025-03-31 0001892316 lddc:ZhouHongxiaoMember 2024-06-30 0001892316 lddc:ZhangLiangMember 2025-03-31 0001892316 lddc:ZhangLiangMember 2024-06-30 0001892316 country:US 2024-07-01 2025-03-31 0001892316 country:HK us-gaap:TaxYear2019Member 2024-07-01 2025-03-31 0001892316 country:HK us-gaap:TaxYear2020Member 2024-07-01 2025-03-31 0001892316 country:CN lddc:LongduoduoHealthTechnologyAndSubsidiariesMember 2024-07-01 2025-03-31 0001892316 country:CN 2025-03-31 0001892316 country:CN 2024-03-31 0001892316 lddc:LongduoduoHealthTechnologyAndSubsidiariesMember 2024-07-01 2025-03-31 0001892316 country:CN 2024-07-01 2025-03-31 0001892316 country:CN 2023-07-01 2024-03-31 0001892316 country:US 2023-07-01 2024-03-31 0001892316 lddc:USFederalMember 2024-07-01 2025-03-31 0001892316 lddc:USFederalMember 2023-07-01 2024-03-31 0001892316 us-gaap:StateAdministrationOfTaxationChinaMember 2024-07-01 2025-03-31 0001892316 lddc:ChenghengMember 2024-11-20 0001892316 lddc:ChenghengMember 2024-11-20 2024-11-20 0001892316 lddc:LongduoduoHealthTechnologyMember 2024-03-11 0001892316 lddc:LongduoduoHealthTechnologyMember 2024-03-11 2024-03-11 0001892316 lddc:TianjuMember 2024-04-01 0001892316 lddc:TianjuMember 2024-04-01 2024-04-01 0001892316 lddc:MongoliaChuangfuhuiEnterpriseManagementCoLtdMember 2024-08-14 0001892316 lddc:MongoliaChuangfuhuiEnterpriseManagementCoLtdMember 2024-08-14 2024-08-14 0001892316 srt:MinimumMember 2025-03-31 0001892316 srt:MaximumMember 2025-03-31 0001892316 srt:MinimumMember lddc:BorrowingRateMember 2024-07-01 2025-03-31 0001892316 srt:MaximumMember lddc:BorrowingRateMember 2024-07-01 2025-03-31 0001892316 2023-09-21 0001892316 us-gaap:CommonStockMember 2023-09-21 2023-09-21 0001892316 lddc:LongduoduoMember 2025-02-19 2025-02-19 0001892316 lddc:QingguoMember 2025-03-31 0001892316 lddc:ChenghengMember 2025-03-31 0001892316 lddc:RongbinMember 2025-03-31 0001892316 lddc:TianjuMember 2025-03-31 0001892316 lddc:LongduoduoHealthTechnologyFromLongduoduoHKMember us-gaap:SubsequentEventMember 2025-04-02 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CNY iso4217:HKD utr:sqm iso4217:NPR

Longduoduo Co Ltd 10-Q